AI-powered search
a

AAD: Berdazimer Gel Clears Molluscum Contagiosum Lesions

Lesion reduction seen by week 4, with continuous improvement over time; treatment-emergent adverse events mainly mild

By Dermsquared Editorial Team | March 30, 2022

For patients with molluscum contagiosum (MC), topical berdazimer gel 10.3 percent is associated with a significant reduction in lesion count by four weeks, according to a study presented at the annual meeting of the American Academy of Dermatology, held from March 25 to 29 in Boston.

John C. Browning, M.D., from Texas Dermatology in San Antonio, and colleagues conducted a multicenter, randomized, vehicle-controlled trial to examine the efficacy and safety of berdazimer 10.3 percent for the treatment of MC in 891 participants. A total of 447 and 444 patients with three to 70 raised and palpable molluscum lesions were randomly assigned to vehicle or berdazimer, respectively, for 12 weeks.

The researchers found that significantly more patients receiving berdazimer had complete clearance of all lesions by week 4 (7.2 versus 3.6 percent), week 8 (19.6 versus 11.6 percent), and week 12 (32.4 versus 19.7 percent). At least one treatment-emergent adverse event (TEAE) occurred in 23.0 and 43.0 percent of patients receiving vehicle and berdazimer, respectively; 0.7 and 4.1 percent of patients, respectively, had at least one TEAE leading to study drug discontinuation. Application site pain and erythema were the most common TEAEs; pain was mostly transient. Erythema was the most frequent local skin reaction and occurred more often in berdazimer-treated patients.

"In B-SIMPLE4, berdazimer 10.3 percent once-daily treatment, MC showed lesion count reduction by four weeks, with continuous improvement over time," the authors write.

Several authors disclosed financial ties to Novan, which manufactures berdazimer and funded the study.

More Information

Loading...
Dermsquared

The leading solutions platform for dermatology professionals to elevate patient care.

Contact Us

Support

Subscribe now

Enter your email to get the latest updates.

© 2024 dermsquared | All Rights Reserved